Table 3.
Subdistribution hazard ratios for single lung function parameters after allo-HCT at day 100 for BOS incidence.
| Subsdistribution hazard ratio estimates for BOS incidence of patients surviving at least 100 days with available PFTs (n = 200/245) | Median time from selected PFT parameters d + 100 to BOS (days) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Parameter before allo-HCT | Parameter at day 100 after allo-HCT | |||||||||
| n | p value | SHR | 95% CI | n | p value | SHR | 95% CI | |||
| FEV1/FVC < 0.80 ratio | 72 | 0.35 | 1.31 | 0.75, 2.30 | 86 | 0.08 | 1.63 | 0.94, 2.82 | 268 | |
| FEV1/FVC < 0.70 ratio | 12 | 0.11 | 2.17 | 0.84, 5.73 | 18 | 0.001 | 3.47 | 1.68, 7.14 | 291 | |
| FEV1 < median (99% of predicted) | 90 | 0.002 | 2.54 | 1.41, 4.58 | 115 | 0.001 | 4.10 | 2.00, 8.43 | 164 | |
| FEV1 < 75% predicted | 8 | 0.12 | 2.20 | 0.82, 5.84 | 23 | 0.03 | 2.25 | 1.09, 4.66 | 386 | |
| RV > 120% predicted | 66 | 0.37 | 1.29 | 0.74, 2.25 | 63 | 0.97 | 0.98 | 0.54, 1.78 | 171 | |
| RV/TLC > 0.45 ratio | 13 | 0.86 | 0.90 | 0.27, 2.97 | 22 | 0.02 | 2.57 | 1.23, 5.36 | 182 | |
| TLC < 80% predicted | 15 | 0.11 | 0.21 | 0.31, 1.41 | 34 | 0.14 | 1.64 | 0.84, 3.18 | 329 | |
| MEF50 < 50% predicted | 30 | 0.12 | 1.66 | 0.87, 3.17 | 43 | 0.001 | 3.17 | 1.82, 5.51 | 379 | |
| MEF50 < 35% predicted | 6 | 0.67 | 1.30 | 0.38, 4.50 | 14 | 0.001 | 5.19 | 2.58, 10.4 | 350 | |
| MEF25 < 35% predicted | 11 | 0.41 | 1.48 | 0.57, 3.84 | 62 | 0.001 | 3.29 | 1.89, 5.72 | 393 | |
| MEF25 < 25% predicted | 6 | 0.67 | 1.30 | 0.38, 4.50 | 24 | 0.001 | 3.42 | 1.88, 6.23 | 277 | |
| DLCOc SB < 80% predicted | 97 | 0.44 | 1.28 | 0.68, 2.39 | 97 | 0.12 | 1.58 | 0.88, 2.83 | 271 | |
| DLCOc SB < 60% predicted | 20 | 0.50 | 1.35 | 0.55, 3.32 | 20 | 0.52 | 1.22 | 0.66, 2.24 | 321 | |
Patients surviving 100 days and with available pulmonary function tests were selected for the analysis (200/245, 82%). Subdistribution hazard ratios (SHR) and confidence intervals (CI) for single pulmonary function test (PFT) values at day 100 after allo-HCT were estimated for BOS in univariate analysis using the Fine and Gray regression model in the presence of competing risks. Cut-off values for PFT were chosen from the significant PFT parameters before allo-HCT and previous publications (Duque-Afonso et al. 2018). Only patients surviving 100 days after allo-HCT and with pulmonary function test (PFT) within the first 100 days after allo-HCT were included in this analysis. Median time from selected PFT parameters from d + 100 to BOS was calculated only for patients developing BOS.
BOS bronchiolitis obliterans syndrome, PFT pulmonary function tests, allo-HCT allogenic hematopoietic cell transplantation, FEV1 forced expiratory volume in 1 second (FEV1), FVC forced vital capacity, RV residual volume, TLC total lung capacity, MEF50 mid-expiratory flow 50%, MEF25 mid-expiratory flow 25%, DLCOc SB carbon monoxide diffusion capacity corrected for hemoglobin.